Skip to main content
NCBI home page
Proceedings of the Royal Society B: Biological Sciences logoLink to Proceedings of the Royal Society B: Biological Sciences
. 2003 Mar 7;270(1514):545–554. doi: 10.1098/rspb.2002.2241

The de novo selection of drug-resistant malaria parasites.

N J White 1, W Pongtavornpinyo 1
PMCID: PMC1691263  PMID: 12641911

Abstract

Antimalarial drug resistance emerges de novo predominantly in areas of low malaria transmission. Because of the logarithmic distribution of parasite numbers in human malaria infections, inadequately treated high biomass infections are a major source of de novo antimalarial resistance, whereas use of antimalarial prophylaxis provides a low resistance selection risk. Slowly eliminated antimalarials encourage resistance largely by providing a selective filter for resistant parasites acquired from others, and not by selecting resistance de novo. The de novo emergence of resistance can be prevented by use of antimalarial combinations. Artemisinin derivative combinations are particularly effective. Ensuring adequate treatment of the relatively few heavily infected patients would slow the emergence of resistance.

Full Text

The Full Text of this article is available as a PDF (281.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Austin D. J., Anderson R. M. Studies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models. Philos Trans R Soc Lond B Biol Sci. 1999 Apr 29;354(1384):721–738. doi: 10.1098/rstb.1999.0425. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. BURGESS R. W., YOUNG M. D. The development of pyrimethamine resistance by Plasmodium falciparum. Bull World Health Organ. 1959;20(1):37–46. [PMC free article] [PubMed] [Google Scholar]
  3. Bloland P. B., Ettling M., Meek S. Combination therapy for malaria in Africa: hype or hope? Bull World Health Organ. 2003 Nov 17;78(12):1378–1388. [PMC free article] [PubMed] [Google Scholar]
  4. Brockman A., Price R. N., van Vugt M., Heppner D. G., Walsh D., Sookto P., Wimonwattrawatee T., Looareesuwan S., White N. J., Nosten F. Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Trans R Soc Trop Med Hyg. 2000 Sep-Oct;94(5):537–544. doi: 10.1016/s0035-9203(00)90080-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chawira A. N., Warhurst D. C., Robinson B. L., Peters W. The effect of combinations of qinghaosu (artemisinin) with standard antimalarial drugs in the suppressive treatment of malaria in mice. Trans R Soc Trop Med Hyg. 1987;81(4):554–558. doi: 10.1016/0035-9203(87)90404-4. [DOI] [PubMed] [Google Scholar]
  6. Cowman A. F., Galatis D., Thompson J. K. Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):1143–1147. doi: 10.1073/pnas.91.3.1143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Curtis C. F., Otoo L. N. A simple model of the build-up of resistance to mixtures of anti-malarial drugs. Trans R Soc Trop Med Hyg. 1986;80(6):889–892. doi: 10.1016/0035-9203(86)90248-8. [DOI] [PubMed] [Google Scholar]
  8. Day N. P., Pham T. D., Phan T. L., Dinh X. S., Pham P. L., Ly V. C., Tran T. H., Nguyen T. H., Bethell D. B., Nguyan H. P. Clearance kinetics of parasites and pigment-containing leukocytes in severe malaria. Blood. 1996 Dec 15;88(12):4694–4700. [PubMed] [Google Scholar]
  9. Dye C., Williams B. G. Multigenic drug resistance among inbred malaria parasites. Proc Biol Sci. 1997 Jan 22;264(1378):61–67. doi: 10.1098/rspb.1997.0009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hastings I. M., D'Alessandro U. Modelling a predictable disaster: the rise and spread of drug-resistantmalaria. Parasitol Today. 2000 Aug;16(8):340–347. doi: 10.1016/s0169-4758(00)01707-5. [DOI] [PubMed] [Google Scholar]
  11. Hastings Ian M., Watkins William M., White Nicholas J. The evolution of drug-resistant malaria: the role of drug elimination half-life. Philos Trans R Soc Lond B Biol Sci. 2002 Apr 29;357(1420):505–519. doi: 10.1098/rstb.2001.1036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. JEFFERY G. M., EYLES D. E. Infectivity to mosquitoes of Plasmodium falciparum as related to gametocyte density and duration of infection. Am J Trop Med Hyg. 1955 Sep;4(5):781–789. doi: 10.4269/ajtmh.1955.4.781. [DOI] [PubMed] [Google Scholar]
  13. Korsinczky M., Chen N., Kotecka B., Saul A., Rieckmann K., Cheng Q. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother. 2000 Aug;44(8):2100–2108. doi: 10.1128/aac.44.8.2100-2108.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Lipsitch M., Levin B. R. The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother. 1997 Feb;41(2):363–373. doi: 10.1128/aac.41.2.363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Looareesuwan S., Viravan C., Webster H. K., Kyle D. E., Hutchinson D. B., Canfield C. J. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg. 1996 Jan;54(1):62–66. doi: 10.4269/ajtmh.1996.54.62. [DOI] [PubMed] [Google Scholar]
  16. Marsh K. Malaria disaster in Africa. Lancet. 1998 Sep 19;352(9132):924–924. doi: 10.1016/S0140-6736(05)61510-3. [DOI] [PubMed] [Google Scholar]
  17. Martin D. C., Arnold J. D. The effect of parasite populations on the curative action of pyrimethamine. Trans R Soc Trop Med Hyg. 1968;62(3):379–384. doi: 10.1016/0035-9203(68)90089-8. [DOI] [PubMed] [Google Scholar]
  18. Nosten F., ter Kuile F., Chongsuphajaisiddhi T., Luxemburger C., Webster H. K., Edstein M., Phaipun L., Thew K. L., White N. J. Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet. 1991 May 11;337(8750):1140–1143. doi: 10.1016/0140-6736(91)92798-7. [DOI] [PubMed] [Google Scholar]
  19. Nosten F., van Vugt M., Price R., Luxemburger C., Thway K. L., Brockman A., McGready R., ter Kuile F., Looareesuwan S., White N. J. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet. 2000 Jul 22;356(9226):297–302. doi: 10.1016/s0140-6736(00)02505-8. [DOI] [PubMed] [Google Scholar]
  20. Nzila A. M., Nduati E., Mberu E. K., Hopkins Sibley C., Monks S. A., Winstanley P. A., Watkins W. M. Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate Pyrimethamine/Sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum. J Infect Dis. 2000 Jun 5;181(6):2023–2028. doi: 10.1086/315520. [DOI] [PubMed] [Google Scholar]
  21. Paget-McNicol S., Saul A. Mutation rates in the dihydrofolate reductase gene of Plasmodium falciparum. Parasitology. 2001 May;122(Pt 5):497–505. doi: 10.1017/s0031182001007739. [DOI] [PubMed] [Google Scholar]
  22. Peters W. Drug resistance in malaria--a perspective. Trans R Soc Trop Med Hyg. 1969;63(1):25–45. [PubMed] [Google Scholar]
  23. Peters W. The prevention of antimalarial drug resistance. Pharmacol Ther. 1990;47(3):499–508. doi: 10.1016/0163-7258(90)90067-c. [DOI] [PubMed] [Google Scholar]
  24. Ponnudurai T., Lensen A. H., van Gemert G. J., Bolmer M. G., Meuwissen J. H. Feeding behaviour and sporozoite ejection by infected Anopheles stephensi. Trans R Soc Trop Med Hyg. 1991 Mar-Apr;85(2):175–180. doi: 10.1016/0035-9203(91)90012-n. [DOI] [PubMed] [Google Scholar]
  25. Price R., Luxemburger C., van Vugt M., Nosten F., Kham A., Simpson J., Looareesuwan S., Chongsuphajaisiddhi T., White N. J. Artesunate and mefloquine in the treatment of uncomplicated multidrug-resistant hyperparasitaemic falciparum malaria. Trans R Soc Trop Med Hyg. 1998 Mar-Apr;92(2):207–211. doi: 10.1016/s0035-9203(98)90750-7. [DOI] [PubMed] [Google Scholar]
  26. Price R., Nosten F., Simpson J. A., Luxemburger C., Phaipun L., ter Kuile F., van Vugt M., Chongsuphajaisiddhi T., White N. J. Risk factors for gametocyte carriage in uncomplicated falciparum malaria. Am J Trop Med Hyg. 1999 Jun;60(6):1019–1023. doi: 10.4269/ajtmh.1999.60.1019. [DOI] [PubMed] [Google Scholar]
  27. Rathod P. K., McErlean T., Lee P. C. Variations in frequencies of drug resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9389–9393. doi: 10.1073/pnas.94.17.9389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Reed M. B., Saliba K. J., Caruana S. R., Kirk K., Cowman A. F. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature. 2000 Feb 24;403(6772):906–909. doi: 10.1038/35002615. [DOI] [PubMed] [Google Scholar]
  29. Rosenberg R., Wirtz R. A., Schneider I., Burge R. An estimation of the number of malaria sporozoites ejected by a feeding mosquito. Trans R Soc Trop Med Hyg. 1990 Mar-Apr;84(2):209–212. doi: 10.1016/0035-9203(90)90258-g. [DOI] [PubMed] [Google Scholar]
  30. Simpson J. A., Aarons L., Collins W. E., Jeffery G. M., White N. J. Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection. Parasitology. 2002 Mar;124(Pt 3):247–263. doi: 10.1017/s0031182001001202. [DOI] [PubMed] [Google Scholar]
  31. Simpson J. A., Watkins E. R., Price R. N., Aarons L., Kyle D. E., White N. J. Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob Agents Chemother. 2000 Dec;44(12):3414–3424. doi: 10.1128/aac.44.12.3414-3424.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Smith T., Schellenberg J. A., Hayes R. Attributable fraction estimates and case definitions for malaria in endemic areas. Stat Med. 1994 Nov 30;13(22):2345–2358. doi: 10.1002/sim.4780132206. [DOI] [PubMed] [Google Scholar]
  33. Snow R. W., Craig M., Deichmann U., Marsh K. Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population. Bull World Health Organ. 1999;77(8):624–640. [PMC free article] [PubMed] [Google Scholar]
  34. Su X., Kirkman L. A., Fujioka H., Wellems T. E. Complex polymorphisms in an approximately 330 kDa protein are linked to chloroquine-resistant P. falciparum in Southeast Asia and Africa. Cell. 1997 Nov 28;91(5):593–603. doi: 10.1016/s0092-8674(00)80447-x. [DOI] [PubMed] [Google Scholar]
  35. Trape J. F., Pison G., Preziosi M. P., Enel C., Desgrées du Loû A., Delaunay V., Samb B., Lagarde E., Molez J. F., Simondon F. Impact of chloroquine resistance on malaria mortality. C R Acad Sci III. 1998 Aug;321(8):689–697. doi: 10.1016/s0764-4469(98)80009-7. [DOI] [PubMed] [Google Scholar]
  36. Watkins W. M., Mberu E. K., Winstanley P. A., Plowe C. V. More on 'the efficacy of antifolate antimalarial combinations in Africa'. Parasitol Today. 1999 Apr;15(4):131–132. doi: 10.1016/s0169-4758(99)01419-2. [DOI] [PubMed] [Google Scholar]
  37. Watkins W. M., Mosobo M. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg. 1993 Jan-Feb;87(1):75–78. doi: 10.1016/0035-9203(93)90431-o. [DOI] [PubMed] [Google Scholar]
  38. White N. J. Antimalarial pharmacokinetics and treatment regimens. Br J Clin Pharmacol. 1992 Jul;34(1):1–10. doi: 10.1111/j.1365-2125.1992.tb04100.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. White N. J. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother. 1997 Jul;41(7):1413–1422. doi: 10.1128/aac.41.7.1413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. White N. J., van Vugt M., Ezzet F. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet. 1999 Aug;37(2):105–125. doi: 10.2165/00003088-199937020-00002. [DOI] [PubMed] [Google Scholar]
  41. White N. Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci. 1999 Apr 29;354(1384):739–749. doi: 10.1098/rstb.1999.0426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. White N. Antimalarial drug resistance and mortality in falciparum malaria. Trop Med Int Health. 1999 Jul;4(7):469–470. doi: 10.1046/j.1365-3156.1999.00435.x. [DOI] [PubMed] [Google Scholar]
  43. ter Kuile F. O., Luxemburger C., Nosten F., Thwai K. L., Chongsuphajaisiddhi T., White N. J. Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg. 1995 Nov-Dec;89(6):660–664. doi: 10.1016/0035-9203(95)90435-2. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the Royal Society B: Biological Sciences are provided here courtesy of The Royal Society

RESOURCES